General Information:

Id: 3,646 (click here to show other Interactions for entry)
Diseases: Diabetes mellitus, type II - [OMIM]
Fatty liver disease, nonalcoholic
Insulin resistance
Reference: Fuchs M(2012) Non-alcoholic Fatty liver disease: the bile Acid-activated farnesoid x receptor as an emerging treatment target J Lipids 2012 [PMID: 22187656]

Interaction Information:

Comment As FXR is expressed in rodent hepatic stellate cells that play a critical role in hepatic fibrosis, it is not surprising that FXR agonists protect against liver fibrosis. This appears to be mediated by a decreased hepatic expression of various profibrotic growth factors including transforming growth factor beta1, tissue inhibitor of metalloproteinase 1, alpha1(I) collagen, alpha smooth muscle actin, matrix metalloproteinase 2 and alpha2(I) collagen, and microRNA-29a. However, if this mechanism is also operational in humans with a lower expression level of FXR remains to be determined. These data suggest that targeting FXR may impact progression from NAFLD to NASH.
Formal Description
Interaction-ID: 34662



decreases_expression of



in liver
Drugbank entries Show/Hide entries for NR1H4 or TGFB1